AU2016325446B2 - Novel compositions and methods for treating or preventing dermal disorders - Google Patents

Novel compositions and methods for treating or preventing dermal disorders Download PDF

Info

Publication number
AU2016325446B2
AU2016325446B2 AU2016325446A AU2016325446A AU2016325446B2 AU 2016325446 B2 AU2016325446 B2 AU 2016325446B2 AU 2016325446 A AU2016325446 A AU 2016325446A AU 2016325446 A AU2016325446 A AU 2016325446A AU 2016325446 B2 AU2016325446 B2 AU 2016325446B2
Authority
AU
Australia
Prior art keywords
cells
rapamycin
dermal
nrtis
mitochondrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016325446A
Other languages
English (en)
Other versions
AU2016325446A1 (en
Inventor
Ashley AZAR
Timothy NACARELLI
Christian Sell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drexel University
Original Assignee
Drexel University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drexel University filed Critical Drexel University
Publication of AU2016325446A1 publication Critical patent/AU2016325446A1/en
Application granted granted Critical
Publication of AU2016325446B2 publication Critical patent/AU2016325446B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016325446A 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders Active AU2016325446B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232228P 2015-09-24 2015-09-24
US62/232,228 2015-09-24
PCT/US2016/052442 WO2017053222A1 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders

Publications (2)

Publication Number Publication Date
AU2016325446A1 AU2016325446A1 (en) 2018-04-19
AU2016325446B2 true AU2016325446B2 (en) 2021-05-13

Family

ID=58387119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016325446A Active AU2016325446B2 (en) 2015-09-24 2016-09-19 Novel compositions and methods for treating or preventing dermal disorders

Country Status (9)

Country Link
US (3) US10695326B2 (https=)
EP (2) EP4729121A2 (https=)
JP (3) JP2018528236A (https=)
KR (1) KR20180081501A (https=)
CN (2) CN115645534A (https=)
AU (1) AU2016325446B2 (https=)
CA (1) CA3037469C (https=)
ES (1) ES3060762T3 (https=)
WO (1) WO2017053222A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
KR20180081501A (ko) * 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
WO2018031789A1 (en) * 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CA3115691A1 (en) * 2018-10-11 2020-04-16 Drexel University Methods for treating or preventing skin conditions
US20210353701A1 (en) * 2018-11-02 2021-11-18 Shiseido Company, Ltd. Ultraviolet light-induced inflammation suppressing agent comprising alternative autophagy inducing agent
KR102132921B1 (ko) * 2018-12-13 2020-07-13 영남대학교 산학협력단 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
US20100260733A1 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti aging agents and methods to identify them
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
EP2671583A1 (en) * 2011-01-31 2013-12-11 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
AU2013204219B2 (en) * 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
US20150140036A1 (en) * 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20040180430A1 (en) * 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
WO2005010010A1 (en) 2003-07-16 2005-02-03 Wyeth Cci-779 isomer c
US20050250805A1 (en) * 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
CA2601694A1 (en) 2005-03-14 2006-09-21 Macrochem Corporation Enhancement of macrolide penetration through human skin
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
MXPA06008797A (es) * 2006-08-03 2008-02-04 Fernando Ahumada Ayala Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus.
WO2008143928A1 (en) 2007-05-15 2008-11-27 Puretech Ventures Methods and compositions for treating skin conditions
EP2362866B1 (en) 2008-11-11 2015-07-08 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US20130102572A1 (en) 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
US20150202187A1 (en) 2012-06-26 2015-07-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
KR20180081501A (ko) 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2009046436A1 (en) * 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
US20100260733A1 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti aging agents and methods to identify them
AU2013204219B2 (en) * 2009-04-10 2015-05-07 Haiyan Qi Novel anti-aging agents and methods to identify them
WO2011079154A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
EP2671583A1 (en) * 2011-01-31 2013-12-11 Osaka University Externally-used drug for treating skin disorder and method for producing same
US20140377285A1 (en) * 2011-11-08 2014-12-25 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
US20150140036A1 (en) * 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3352755A4 (en) 2019-04-03
US20180280362A1 (en) 2018-10-04
JP2022009168A (ja) 2022-01-14
JP7332666B2 (ja) 2023-08-23
CA3037469A1 (en) 2017-03-30
JP2018528236A (ja) 2018-09-27
JP7573078B2 (ja) 2024-10-24
US10695326B2 (en) 2020-06-30
ES3060762T3 (en) 2026-03-30
WO2017053222A1 (en) 2017-03-30
EP3352755A1 (en) 2018-08-01
CN108348508A (zh) 2018-07-31
US20220031673A1 (en) 2022-02-03
HK1258696A1 (en) 2019-11-15
US20200281903A1 (en) 2020-09-10
AU2016325446A1 (en) 2018-04-19
EP4729121A2 (en) 2026-04-22
KR20180081501A (ko) 2018-07-16
JP2023154020A (ja) 2023-10-18
CA3037469C (en) 2024-04-16
US11179374B2 (en) 2021-11-23
EP3352755B1 (en) 2025-12-24
CN115645534A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7573078B2 (ja) 真皮障害を治療または予防するための新規組成物および方法
US20240108645A1 (en) Senescence and senescence associated secretory phenotype
Vin et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Lamming et al. Rapalogs and mTOR inhibitors as anti-aging therapeutics
US9084790B2 (en) Compositions and methods for treating skin cancer associated diseases
WO2019104065A1 (en) Anti-aging methods and compositions
US9358236B2 (en) Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
US20100009997A1 (en) Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
US20200108074A1 (en) Combinations of chk1- and wee1- inhibitors
CA2577442A1 (en) Pde5 inhibitor compositions and methods for treating cardiac indications
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
US9629851B2 (en) ROCK in combination with MAPK pathway
KR20120133389A (ko) 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
HK1258696B (en) Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis
Liao et al. Kinase Inhibitors for the Treatment of Brain Diseases
US20240390386A1 (en) Cdk8/19 inhibitors for preventing drug resistance
Keser et al. Comparative Analysis of CDK4/6 Inhibitors (Ribociclib and Palbociclib) combined with Enzalutamide in Triple-negative breast cancer cells
Khoperia et al. Effect of metformin on the medullary thyroid cancer cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)